| review article | Q7318358 |
| scholarly article | Q13442814 |
| P50 | author | Robert A Bonomo | Q62516257 |
| P2093 | author name string | Federico Perez | |
| Kristine M Hujer | |||
| Andrea Endimiani | |||
| P2860 | cites work | Mutagenesis of amino acid residues in the SHV-1 beta-lactamase: the premier role of Gly238Ser in penicillin and cephalosporin resistance | Q73852591 |
| Comparative activities of cefepime and piperacillin/tazobactam tested against a global collection of Escherichia coli and Klebsiella spp. with an ESBL phenotype | Q79399849 | ||
| Influx of extended-spectrum beta-lactamase-producing enterobacteriaceae into the hospital | Q82703807 | ||
| Extended-spectrum beta-lactamases: a clinical update | Q24534999 | ||
| Extended-spectrum beta-lactamases in the 21st century: characterization, epidemiology, and detection of this important resistance threat | Q24550671 | ||
| A functional classification scheme for beta-lactamases and its correlation with molecular structure | Q24677460 | ||
| Carbapenemases: the versatile beta-lactamases | Q24685034 | ||
| Nosocomial bloodstream infections caused by Klebsiella pneumoniae: impact of extended-spectrum beta-lactamase (ESBL) production on clinical outcome in a hospital with high ESBL prevalence | Q25257162 | ||
| The high resolution crystal structure for class A beta-lactamase PER-1 reveals the bases for its increase in breadth of activity | Q27622638 | ||
| Predicting the emergence of antibiotic resistance by directed evolution and structural analysis | Q27630116 | ||
| Acyl-intermediate structures of the extended-spectrum class A beta-lactamase, Toho-1, in complex with cefotaxime, cephalothin, and benzylpenicillin | Q27639628 | ||
| Ultrahigh resolution structure of a class A beta-lactamase: on the mechanism and specificity of the extended-spectrum SHV-2 enzyme | Q27640937 | ||
| Recognition and resistance in TEM beta-lactamase | Q27641672 | ||
| Crystal structure of extended-spectrum beta-lactamase Toho-1: insights into the molecular mechanism for catalytic reaction and substrate specificity expansion | Q27641978 | ||
| Crystal Structure of KPC-2: Insights into Carbapenemase Activity in Class A β-Lactamases † , ‡ | Q27644490 | ||
| Crystal structure of the E166A mutant of extended-spectrum beta-lactamase Toho-1 at 1.8 A resolution | Q27766758 | ||
| The antibiotic resistome: the nexus of chemical and genetic diversity | Q29544028 | ||
| The CTX-M beta-lactamase pandemic. | Q30356558 | ||
| Prevalence and antimicrobial susceptibility data for extended-spectrum beta-lactamase- and AmpC-producing Enterobacteriaceae from the MYSTIC Program in Europe and the United States (1997-2004). | Q33229748 | ||
| Kinship and diversification of bacterial penicillin-binding proteins and beta-lactamases | Q33690362 | ||
| Proteus mirabilis bloodstream infections: risk factors and treatment outcome related to the expression of extended-spectrum beta-lactamases | Q33883791 | ||
| Detection and reporting of organisms producing extended-spectrum beta-lactamases: survey of laboratories in Connecticut | Q33964309 | ||
| Detection of extended-spectrum beta-lactamases in clinical isolates of Enterobacter cloacae and Enterobacter aerogenes. | Q33965292 | ||
| Outcome of cephalosporin treatment for serious infections due to apparently susceptible organisms producing extended-spectrum beta-lactamases: implications for the clinical microbiology laboratory. | Q33972587 | ||
| Bacterial resistance to beta-lactam antibiotics: compelling opportunism, compelling opportunity | Q33984936 | ||
| Clinical and molecular analysis of extended-spectrum {beta}-lactamase-producing enterobacteria in the community setting. | Q34073299 | ||
| Bloodstream infections by extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in children: epidemiology and clinical outcome | Q34106854 | ||
| Therapeutic challenges associated with extended-spectrum, beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae | Q34249399 | ||
| Amino acid substitutions at Ambler position Gly238 in the SHV-1 beta-lactamase: exploring sequence requirements for resistance to penicillins and cephalosporins | Q34253358 | ||
| In vitro activity of fosfomycin against extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae: comparison of susceptibility testing procedures. | Q34301565 | ||
| Bloodstream infections caused by extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae: risk factors, molecular epidemiology, and clinical outcome | Q34351978 | ||
| Rapid spread of carbapenem-resistant Klebsiella pneumoniae in New York City: a new threat to our antibiotic armamentarium | Q34429494 | ||
| Colistin: the re-emerging antibiotic for multidrug-resistant Gram-negative bacterial infections | Q34560321 | ||
| Clinical correlation of the CLSI susceptibility breakpoint for piperacillin- tazobactam against extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella species | Q34680546 | ||
| Spread of Escherichia coli strains with high-level cefotaxime and ceftazidime resistance between the community, long-term care facilities, and hospital institutions | Q34720052 | ||
| Pharmacokinetics-Pharmacodynamics of Cefepime and Piperacillin- Tazobactam against Escherichia coli and Klebsiella pneumoniae Strains Producing Extended-Spectrum β-Lactamases: Report from the ARREST Program | Q34937147 | ||
| CTX-M-type extended-spectrum beta-lactamases in Italy: molecular epidemiology of an emerging countrywide problem | Q34973754 | ||
| Growing group of extended-spectrum beta-lactamases: the CTX-M enzymes | Q35006613 | ||
| The impact of beta-lactamases on the development of novel antimicrobial agents. | Q35032844 | ||
| Extended-spectrum and inhibitor-resistant TEM-type beta-lactamases: mutations, specificity, and three-dimensional structure | Q35120519 | ||
| AmpC beta-lactamases: what do we need to know for the future? | Q35140531 | ||
| Utility of NCCLS guidelines for identifying extended-spectrum beta-lactamases in non-Escherichia coli and Non-Klebsiella spp. of Enterobacteriaceae | Q35552314 | ||
| Extended-spectrum beta-lactamases in enterobacteriaceae in Buenos Aires, Argentina, public hospitals | Q35685785 | ||
| CTX-M beta-lactamase-producing Escherichia coli in French hospitals: prevalence, molecular epidemiology, and risk factors | Q35690509 | ||
| Molecular epidemiology of CTX-M-producing Escherichia coli in the Calgary Health Region: emergence of CTX-M-15-producing isolates | Q35758933 | ||
| Spread of extended-spectrum beta-lactamase CTX-M-producing escherichia coli clinical isolates in community and nosocomial environments in Portugal | Q35840807 | ||
| Nosocomial outbreak due to extended-spectrum-beta-lactamase- producing Enterobacter cloacae in a cardiothoracic intensive care unit | Q35947527 | ||
| Emergence of Enterobacteriaceae producing extended-spectrum beta-lactamases (ESBLs) in the community | Q36139832 | ||
| Epidemiology and clinical features of infections caused by extended-spectrum beta-lactamase-producing Escherichia coli in nonhospitalized patients. | Q36598540 | ||
| CTX-M: changing the face of ESBLs in Europe | Q36678524 | ||
| Characterization of TEM-1 beta-lactamase mutants from positions 238 to 241 with increased catalytic efficiency for ceftazidime. | Q36740539 | ||
| Amino acid sequence determinants of beta-lactamase structure and activity | Q36799732 | ||
| Cefepime versus imipenem-cilastatin for treatment of nosocomial pneumonia in intensive care unit patients: a multicenter, evaluator-blind, prospective, randomized study | Q36880729 | ||
| Cephalosporin substrate specificity determinants of TEM-1 beta-lactamase | Q36889931 | ||
| More extended-spectrum beta-lactamases | Q37520309 | ||
| Detection of extended-spectrum beta-lactamases in klebsiellae with the Oxoid combination disk method. | Q39462189 | ||
| Sampling the antibiotic resistome | Q40357052 | ||
| When to include polymyxins in the empirical antibiotic regimen in critically ill patients with fever? A decision analysis approach. | Q40449802 | ||
| Fosfomycin in the treatment of extended spectrum beta-lactamase-producing Escherichia coli-related lower urinary tract infections. | Q40461452 | ||
| Evolution and dissemination of beta-lactamases accelerated by generations of beta-lactam antibiotics | Q41311524 | ||
| Trends in production of extended-spectrum beta-lactamases among enterobacteria of medical interest: report of the second Italian nationwide survey | Q41807595 | ||
| Nationwide study of Escherichia coli and Klebsiella pneumoniae producing extended-spectrum beta-lactamases in Spain | Q41943687 | ||
| Rapid dissemination and diversity of CTX-M extended-spectrum beta-lactamase genes in commensal Escherichia coli isolates from healthy children from low-resource settings in Latin America. | Q42112155 | ||
| Antibiotic coresistance in extended-spectrum-beta-lactamase-producing Enterobacteriaceae and in vitro activity of tigecycline | Q42549433 | ||
| Detection of extended-spectrum beta-lactamases among Enterobacteriaceae by use of semiautomated microbiology systems and manual detection procedures | Q42799124 | ||
| A standard numbering scheme for the class A beta-lactamases | Q42861944 | ||
| Evolution of CTX-M-type beta-lactamases in isolates of Escherichia coli infecting hospital and community patients. | Q43803815 | ||
| Molecular correlation for the treatment outcomes in bloodstream infections caused by Escherichia coli and Klebsiella pneumoniae with reduced susceptibility to ceftazidime | Q43820678 | ||
| Risk factors for the development of extended-spectrum beta-lactamase-producing bacteria in nonhospitalized patients | Q44054169 | ||
| Bacteremia caused by Escherichia coli producing extended-spectrum beta-lactamase: a case-control study of risk factors and outcomes | Q44142354 | ||
| Nosocomial and community-acquired Enterobacter cloacae bloodstream infection: risk factors for and prevalence of SHV-12 in multiresistant isolates in a medical centre | Q44790712 | ||
| Extended-spectrum beta-lactamases in multidrug-resistant Escherichia coli: changing the therapy for hospital-acquired and community-acquired infections | Q44836759 | ||
| Evaluation of a new cefepime-clavulanate ESBL Etest to detect extended-spectrum beta-lactamases in an Enterobacteriaceae strain collection | Q44901126 | ||
| Antibiotic therapy for Klebsiella pneumoniae bacteremia: implications of production of extended-spectrum beta-lactamases | Q44943295 | ||
| Community and hospital spread of Escherichia coli producing CTX-M extended-spectrum beta-lactamases in the UK. | Q45044150 | ||
| Regional variation in the prevalence of extended-spectrum beta-lactamase-producing clinical isolates in the Asia-Pacific region (SENTRY 1998-2002). | Q46216893 | ||
| Clinical implications of extended spectrum beta-lactamase (ESBL) producing Klebsiella species and Escherichia coli on cefepime effectiveness | Q46757334 | ||
| Clinical and molecular epidemiology of extended-spectrum beta-lactamase-producing Escherichia coli as a cause of nosocomial infection or colonization: implications for control | Q46831794 | ||
| High-dose cefepime as an alternative treatment for infections caused by TEM-24 ESBL-producing Enterobacter aerogenes in severely-ill patients. | Q46929782 | ||
| Risk factors for community-onset urinary tract infections due to Escherichia coli harbouring extended-spectrum beta-lactamases | Q46956002 | ||
| Activity of tigecycline against ESBL-producing and AmpC-hyperproducing Enterobacteriaceae from south-east England | Q47588212 | ||
| Outcomes evaluation of patients with ESBL- and non-ESBL-producing Escherichia coli and Klebsiella species as defined by CLSI reference methods: report from the SENTRY Antimicrobial Surveillance Program. | Q51187843 | ||
| Escherichia coli producing CTX-M beta-lactamases in food animals in Hong Kong. | Q53604099 | ||
| CTX-M: changing the face of ESBLs in the UK. | Q53851440 | ||
| Spread of novel expanded-spectrum beta-lactamases in Enterobacteriaceae in a university hospital in the Paris area, France. | Q53854126 | ||
| Epidemiology of ciprofloxacin resistance and its relationship to extended-spectrum beta-lactamase production in Klebsiella pneumoniae isolates causing bacteremia. | Q54058575 | ||
| Multiple antibiotic-resistant Klebsiella and Escherichia coli in nursing homes. | Q54105047 | ||
| Stability of TEM beta-lactamase mutants hydrolyzing third generation cephalosporins. | Q54163512 | ||
| Community emergence of CTX-M type extended-spectrum beta-lactamases among urinary Escherichia coli from women. | Q54441555 | ||
| Prevalence of community-occurring extended spectrum beta-lactamase-producing Enterobacteriaceae in Brazil. | Q54442537 | ||
| Analysis of plasmids encoding extended-spectrum beta-lactamases (ESBLs) from Escherichia coli isolated from non-hospitalised patients in Seville. | Q54449575 | ||
| Use of cefepime for the treatment of infections caused by extended spectrum beta-lactamase-producing Klebsiella pneumoniae and Escherichia coli. | Q54452532 | ||
| Bacteremia due to extended-spectrum beta -lactamase-producing Escherichia coli in the CTX-M era: a new clinical challenge. | Q54452583 | ||
| CTX-M-1- and CTX-M-15-type beta-lactamases in clinical Escherichia coli isolates recovered from food-producing animals in France. | Q54454207 | ||
| Performance in detection and reporting beta-lactam resistance phenotypes in Enterobacteriaceae: a nationwide proficiency study in Italian laboratories. | Q54465752 | ||
| TEM beta-lactamase mutants hydrolysing third-generation cephalosporins. A kinetic and molecular modelling analysis. | Q54622202 | ||
| Extended-spectrum -lactamase-producing Enterobacteriaceae in different environments (humans, food, animal farms and sewage) | Q57632258 | ||
| Extended-spectrum beta-lactamases | Q69547842 | ||
| Antibiotic resistance and production of extended-spectrum beta-lactamases amongst Klebsiella spp. from intensive care units in Europe | Q71722506 | ||
| P433 | issue | 5 | |
| P304 | page(s) | 459-469 | |
| P577 | publication date | 2007-09-17 | |
| P1433 | published in | Current Opinion in Pharmacology | Q3007702 |
| P1476 | title | The continuing challenge of ESBLs | |
| P478 | volume | 7 |
| Q64099577 | A DNA aptamer reveals an allosteric site for inhibition in metallo-β-lactamases |
| Q42821270 | A cointegrate-like plasmid that facilitates dissemination by conjugation of the extended-spectrum β-lactamase CTX-M-17. |
| Q37036463 | A novel extended-spectrum β-lactamase, SGM-1, from an environmental isolate of Sphingobium sp |
| Q30986331 | A qPCR and multiplex pyrosequencing assay combined with automated data processing for rapid and unambiguous detection of ESBL-producers Enterobacteriaceae |
| Q51275947 | An evolutionarily conserved allosteric site modulates beta-lactamase activity. |
| Q46231687 | Antibacterial activity of cefditoren against major community-acquired respiratory pathogens recently isolated in Italy |
| Q90671268 | Antibiotic Resistance Profile and Diversity of Subtypes Genes in Escherichia coli Causing Bloodstream Infection in Northern Vietnam |
| Q34456773 | Antibiotic resistance and extended spectrum beta-lactamases: Types, epidemiology and treatment |
| Q35020408 | Antibiotic resistance and prevalence of class 1 and 2 integrons in Escherichia coli isolated from two wastewater treatment plants, and their receiving waters (Gulf of Gdansk, Baltic Sea, Poland). |
| Q35908410 | Antimicrobial Resistance and Molecular Epidemiology of Escherichia coli Causing Bloodstream Infections in Three Hospitals in Shanghai, China |
| Q37628703 | Antimicrobial Resistant Enteropathogenic Escherichia coli and Salmonella spp. in Houseflies Infesting Fish in Food Markets in Zambia |
| Q40047461 | Antimicrobial Susceptibility Pattern of Extended-spectrum Beta-lactamases Producing Organisms Isolated in a Tertiary Care Hospital, Bangladesh |
| Q39456622 | Antimicrobial aptamers for detection and inhibition of microbial pathogen growth. |
| Q93188799 | Assessment of Antibiotic Levels, Multi-Drug Resistant Bacteria and Genetic Biomarkers in the Waters of the Rio Grande River Between the United States-Mexico Border |
| Q92282371 | Beyond Piperacillin-Tazobactam: Cefepime and AAI101 as a Potent β-Lactam-β-Lactamase Inhibitor Combination |
| Q34680304 | Biochemical and structural analysis of inhibitors targeting the ADC-7 cephalosporinase of Acinetobacter baumannii |
| Q38068604 | Bloodstream infections caused by carbapenemase-producing Klebsiella pneumoniae: a clinical perspective |
| Q46283648 | CTX-M-15-producing Shewanella sp. clinical isolate expressing OXA-535, a chromosome-encoded OXA-48 variant, putative progenitor of the plasmid-encoded OXA-436. |
| Q36018566 | Carbapenem therapy for bacteremia due to extended-spectrum-β-lactamase-producing Escherichia coli or Klebsiella pneumoniae: implications of ertapenem susceptibility |
| Q39541312 | Catalytic role of the metal ion in the metallo-beta-lactamase GOB. |
| Q37079350 | Cefepime: a reappraisal in an era of increasing antimicrobial resistance |
| Q39141277 | Characterization of AmpC, CTX-M and MBLs types of β-lactamases in clinical isolates of Klebsiella pneumoniae and Escherichia coli producing Extended Spectrum β-lactamases in Kerman, Iran. |
| Q36708459 | Characterization of Extended-Spectrum Beta-lactamase from Escherichia coli and Klebsiella Species from North Eastern Nigeria |
| Q37292207 | Characterization of multidrug resistant ESBL-producing Escherichia coli isolates from hospitals in Malaysia |
| Q36639972 | Clinico-microbiological study and antibiotic resistance profile of mecA and ESBL gene prevalence in patients with diabetic foot infections |
| Q43168087 | Co-resistance to different classes of antibiotics among ESBL-producers from aquatic systems. |
| Q37450794 | Complete nucleotide sequence of pCTX-M360, an intermediate plasmid between pEL60 and pCTX-M3, from a multidrug-resistant Klebsiella pneumoniae strain isolated in China. |
| Q36039546 | Complete sequence and molecular epidemiology of IncK epidemic plasmid encoding blaCTX-M-14. |
| Q34423146 | Deep sequencing of systematic combinatorial libraries reveals β-lactamase sequence constraints at high resolution |
| Q40095174 | Detection of CTX-M-15 Among Uropathogenic Escherichia coli Isolated from Five Major Hospitals in Tripoli, Libya |
| Q48038420 | Detection of New Delhi metallo-beta-lactamase and extended-spectrum beta-lactamase genes in Escherichia coli isolated from mastitic milk samples |
| Q42258248 | Detection, treatment, and prevention of carbapenemase-producing Enterobacteriaceae: recommendations from an International Working Group. |
| Q35808488 | Differential binding of Co(II) and Zn(II) to metallo-beta-lactamase Bla2 from Bacillus anthracis |
| Q41465584 | Drug susceptibility and molecular epidemiology of Escherichia coli in bloodstream infections in Shanghai, China, 2011-2013. |
| Q35101453 | ESBLs: A Clear and Present Danger? |
| Q33417253 | Efflux pump, the masked side of beta-lactam resistance in Klebsiella pneumoniae clinical isolates |
| Q36305006 | Epidemiology of Carbapenem Resistance among Multi-drug Resistant Enterobacteriaceae in Uganda |
| Q89899478 | Epidemiology of β-Lactamase-Producing Pathogens |
| Q90236679 | Ertapenem for osteoarticular infections in obese patients: a pharmacokinetic study of plasma and bone concentrations |
| Q51571539 | Escherichia coli with extended-spectrum β-lactamase and plasmid-mediated quinolone resistance genes in great cormorants and mallards in Central Europe. |
| Q88984656 | Evaluation of the Bactericidal Activity of Plazomicin and Comparators against Multidrug-Resistant Enterobacteriaceae |
| Q28272040 | Exploring the role of a conserved class A residue in the Ω-Loop of KPC-2 β-lactamase: a mechanism for ceftazidime hydrolysis |
| Q36277409 | Extended spectrum beta lactamase producing organisms causing urinary tract infections in Sri Lanka and their antibiotic susceptibility pattern -A hospital based cross sectional study |
| Q39233531 | Extended spectrum β-lactamase producing Escherichia coli and Klebsiella pneumoniae: critical tools for antibiotic resistance pattern |
| Q37159830 | Extended-spectrum beta-lactamase-producing bacteria isolated from hematologic patients in Manaus, State of Amazonas, Brazil |
| Q45994003 | Extended-spectrum {beta}-lactamases and AmpC {beta}-lactamases in ceftiofur-resistant Salmonella enterica isolates from food and livestock obtained in Germany during 2003-07. |
| Q39250173 | Factors pivotal for designing of nanoantimicrobials: an exposition |
| Q42782099 | Fecal carriage and shedding density of CTX-M extended-spectrum {beta}-lactamase-producing escherichia coli in cattle, chickens, and pigs: implications for environmental contamination and food production |
| Q33434215 | Fine mapping of the sequence requirements for binding of beta-lactamase inhibitory protein (BLIP) to TEM-1 beta-lactamase using a genetic screen for BLIP function |
| Q38196443 | Fragment-based inhibitor discovery against β-lactamase |
| Q33635196 | High diversity of extended-spectrum beta-lactamase-producing bacteria in an urban river sediment habitat |
| Q54198024 | High rate of aminoglycoside resistance in CTX-M-15 producing Klebsiella pneumoniae isolates in Tehran, Iran. |
| Q34800304 | Identification of products of inhibition of GES-2 beta-lactamase by tazobactam by x-ray crystallography and spectrometry |
| Q42111116 | Importance of position 170 in the inhibition of GES-type β-lactamases by clavulanic acid. |
| Q36290815 | In Vivo Evolution of CMY-2 to CMY-33 β-Lactamase in Escherichia coli Sequence Type 131: Characterization of an Acquired Extended-Spectrum AmpC Conferring Resistance to Cefepime |
| Q41769872 | In vivo impact of Met221 substitution in GOB metallo-β-lactamase |
| Q38878895 | Incidence and Outcomes of Infections Caused by Multidrug-Resistant Enterobacteriaceae in Children, 2007-2015. |
| Q64128245 | Incidence and antimicrobial resistance trends in bloodstream infections caused by ESKAPE and Escherichia coli at a large teaching hospital in Rome, a 9-year analysis (2007–2015) |
| Q33613797 | Inhibitor resistance in the KPC-2 beta-lactamase, a preeminent property of this class A beta-lactamase |
| Q43993853 | Investigation and characterization of β-lactam resistance in Escherichia coli strains isolated from bamboo rats (Rhizomys sinensis) in Zhejiang province, China |
| Q47747140 | Isolation of ESBL-producing Bacteria from Sputum in Community-acquired Pneumonia or Healthcare-associated Pneumonia Does Not Indicate the Need for Antibiotics with Activity against This Class |
| Q38314617 | Modifications of the C6-substituent of penicillin sulfones with the goal of improving inhibitor recognition and efficacy |
| Q64236542 | Molecular Characterization of Extended Spectrum β-lactamase and Carbapenemase Producing from a Tertiary Care Hospital |
| Q34249389 | Molecular analysis and risk factors for Escherichia coli producing extended-spectrum β-lactamase bloodstream infection in hematological malignancies |
| Q47118920 | Multi-antibiotic resistant extended-spectrum beta-lactamase producing bacteria pose a challenge to the effective treatment of wound and skin infections. |
| Q47702526 | Multidrug-resistant organisms, wounds and topical antimicrobial protection |
| Q37291349 | Multiresistant Enterobacteriaceae: new threat of an old problem |
| Q39230397 | Next-generation approaches to understand and combat the antibiotic resistome. |
| Q36921676 | Occurrence and characteristics of extended spectrum beta-lactamases-producing Enterobacteriaceae from foods of animal origin |
| Q38945913 | Occurrence of IMP-8, IMP-10, and IMP-13 metallo-β-lactamases located on class 1 integrons and other extended-spectrum β-lactamases in bacterial isolates from Tunisian rivers. |
| Q38945915 | Occurrence of clinical isolates of Klebsiella pneumoniae harboring chromosomally mediated and plasmid-mediated CTX-M-15 β-lactamase in a Tunisian hospital |
| Q34108735 | Oral treatment options for ambulatory patients with urinary tract infections caused by extended-spectrum-beta-lactamase-producing Escherichia coli |
| Q43119295 | PCR-Based Detection of Extended-Spectrum β-Lactamases (bla CTX-M-1 and bla TEM ) in Escherichia coli, Salmonella spp. and Klebsiella pneumoniae Isolated from Pigs in North Eastern India (Mizoram). |
| Q35104348 | Plasmid-Mediated Antibiotic Resistance and Virulence in Gram-negatives: the Klebsiella pneumoniae Paradigm |
| Q24594289 | Prevalence and antibiogram of Extended Spectrum β-Lactamase (ESBL) producing Gram negative bacilli and further molecular characterization of ESBL producing Escherichia coli and Klebsiella spp |
| Q41117625 | Prevalence and characteristics of extended-spectrum β-lactamase genes in Escherichia coli isolated from piglets with post-weaning diarrhea in Heilongjiang province, China |
| Q39325891 | Prevalence and pathogenesis of extended-spectrum beta-lactamase producing Escherichia coli causing urinary tract infection in hospitalized patients |
| Q36857383 | Prevalence of ESBL-Producing Klebsiella pneumoniae Isolates in Tertiary Care Hospital |
| Q40629064 | Prevalence of Extended Spectrum β-Lactamase and Antimicrobial Susceptibility Pattern of Clinical Isolates of Pseudomonas from Patients of Khyber Pakhtunkhwa, Pakistan |
| Q41062335 | Prevalence of β-Lactamase Producing Escherichia coli from Retail Meat in Turkey |
| Q36673614 | Probing the role of Met221 in the unusual metallo-β-lactamase GOB-18. |
| Q41915492 | Pyrosequencing using the single-nucleotide polymorphism protocol for rapid determination of TEM- and SHV-type extended-spectrum beta-lactamases in clinical isolates and identification of the novel beta-lactamase genes blaSHV-48, blaSHV-105, and blaT |
| Q36265453 | Resistance of Undisturbed Soil Microbiomes to Ceftriaxone Indicates Extended Spectrum β-Lactamase Activity |
| Q37182382 | Role of the Zn1 and Zn2 sites in metallo-beta-lactamase L1 |
| Q42550799 | Role of β-lactamase residues in a common interface for binding the structurally unrelated inhibitory proteins BLIP and BLIP-II. |
| Q27677851 | Structural Analysis of the Role of Pseudomonas aeruginosa Penicillin-Binding Protein 5 in -Lactam Resistance |
| Q37165938 | Structure and mechanism of copper- and nickel-substituted analogues of metallo-beta-lactamase L1 |
| Q33962811 | Substrate selectivity and a novel role in inhibitor discrimination by residue 237 in the KPC-2 beta-lactamase |
| Q35192249 | Susceptibility of extended-spectrum-beta-lactamase-producing Enterobacteriaceae according to the new CLSI breakpoints |
| Q57056883 | Synergistic effects of functionally distinct substitutions in β-lactamase variants shed light on the evolution of bacterial drug resistance |
| Q24646623 | Three decades of beta-lactamase inhibitors |
| Q30486102 | Trapping and characterization of a reaction intermediate in carbapenem hydrolysis by B. cereus metallo-beta-lactamase |
| Q36171576 | Understanding the molecular determinants of substrate and inhibitor specificities in the Carbapenemase KPC-2: exploring the roles of Arg220 and Glu276. |
| Q40897433 | Unravelling of a mechanism of resistance to colistin in Klebsiella pneumoniae using atomic force microscopy. |
| Q36607755 | X-ray absorption spectroscopy of metal site speciation in the metallo-β-lactamase BcII from Bacillus cereus. |
| Q54394159 | [Prevalence of the TEM, SHV and CTX-M families of extended-spectrum beta-lactamases in Escherichia coli and Klebsiella spp at the University Hospital of Santa Maria, State of Rio Grande do Sul]. |
| Q36644786 | β-Lactamase Characterization of Gram-Negative Pathogens Recovered from Patients Enrolled in the Phase 2 Trials for Ceftazidime-Avibactam: Clinical Efficacies Analyzed against Subsets of Molecularly Characterized Isolates |
| Q38981257 | β-Lactamases: A Focus on Current Challenges |
Search more.